PHARMACOECONOMIC EVALUATION OF RUFINAMIDE USE FOR THE LENNOX-GASTAUT SYNDROME TREATMENT

PHARMACOECONOMIC EVALUATION OF RUFINAMIDE USE FOR THE LENNOX-GASTAUT SYNDROME TREATMENT

Among epileptic encephalopathies, the Lennox–Gastaut syndrome is considered to be one of the most severe. It is a childhood-onset disease that leads to early disability and mental retardation and is associated with significant costs of medical care and patient nursing. In the Russian Federation, the...

Cijeli opis

Bibliografski detalji
Glavni autori: N. K. Mazina, P. V. Mazin, Yu. V. Kislitsin, E. M. Markova
Format: Članak
Jezik:Russian
Izdano: IRBIS LLC 2016-04-01
Serija:Фармакоэкономика
Teme:
epilepsy
drug resistance
lennox-gastaut syndrome
children-onset epilepsy
antiepileptic drugs
rufinamide
meta-analysis
pharmacoeconomic modelling
“decision-tree” model
Online pristup:https://www.pharmacoeconomics.ru/jour/article/view/132

Internet

https://www.pharmacoeconomics.ru/jour/article/view/132

Slični predmeti